Clinical outcomes of long‐acting risperidone in recent versus long‐term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e‐STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES)
Authors:
- 24 January 2013
- journal article
- research article
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 8 (1) , 39-49
Abstract
Aim: Potential differences in psychiatric clinical outcomes and hospitalization rates before and after the initiation of long-acting risperidone among recently and long-term diagnosed schizophrenia patients were studied. Methods: Data from two observational studies (Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES) and electronic Schizophrenia Treatment Adherence Registry (e-STAR)) were categorized by the recency of their diagnose and compared in several post hoc analyses. Clinical Global Impression of illness Severity (CGI-S) and Global Assessment of Functioning (GAF) scores, as well as symptoms of clinical deterioration (including hospitalization data) at baseline, 12-month (for TIMORES and e-STAR) and 24-month (for e-STAR) follow-up were analysed. Other outcome measures included discontinuation rate, employment status and remission attainment. Results: Statistically significantly differences between recent and long-term diagnosed schizophrenic patients at 12- and 24-month follow-up were found for CGI-S (between P<0.01 and P≤0.001) and GAF (P<0.05) scores. Other differences between both schizophrenic patient groups were found for measures of clinical deterioration, employment status and full symptomatic remission rates at 1 year. Although no consistent difference was found between recent and long-term patient groups for hospitalization parameters, the difference in length of full hospitalization days was statistically significantly different (P<0.01) between e-STAR 'Early' and 'Late' patient groups at both 12- and 24-month endpoints: the mean change from baseline was significantly greater for e-STAR 'Early' at 12 months, but greater for e-STAR 'Late' at 24 months. Conclusions: The findings of the post hoc analyses support the significance of pharmacological interventions, such as long-acting risperidone, in addressing discontinuity issues, especially in recently diagnosed patients. © 2013 Wiley Publishing Asia Pty LtdKeywords
This publication has 36 references indexed in Scilit:
- The heterogeneity of antipsychotic response in the treatment of schizophreniaPsychological Medicine, 2010
- Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disordersInternational Clinical Psychopharmacology, 2010
- EFFICACY AND TOLERABILITY AMONG PATIENTS WITH RECENT ONSET SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTABLE (RLAI)Schizophrenia Research, 2010
- A Randomized Controlled Trial of Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia PatientsThe Journal of Clinical Psychiatry, 2009
- Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studiesClinical Therapeutics, 2008
- Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injectionInternational Clinical Psychopharmacology, 2008
- The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosisPsychological Medicine, 2008
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialThe Lancet, 2008
- Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectableJournal of Psychopharmacology, 2005
- De omvang van de groep van ernstig en langdurig psychisch ziekenTijdschrift voor Geneeskunde, 2002